MedWatch

Professor claims Eli Lilly's tirzepatide could essentially eradicate type 2 diabetes

Professor and consultant Sten Madsbad says that the treatment could be a new start for type 2 diabetes sufferers.

Photo: Morten Germund/Morten Germund /

Eli Lilly’s tirzepatide is ”a new start” within type 2 diabetes and could essentially eradicate the disease, professor Sten Madsbad, who is a consultant at the endocrinology department at Hvidovre hospital, tells Danish journal Sundhedspolitisk Tidsskrift.

This comes after detailed results from a phase III study, Surmount-1, which demonstrated weight loss of up to 22.5% of baseline body weight, were presented at the US diabetes conference, ADA 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs